

 Early Warning System

IFC-48236

Desano Loan



## Quick Facts

<b>Countries</b>	China, India
<b>Specific Location</b>	Zhangshu City, Jiangxi province (China) and Harohalli, Karnataka (India)
<b>Financial Institutions</b>	International Finance Corporation (IFC)
<b>Status</b>	Approved
<b>Bank Risk Rating</b>	B
<b>Voting Date</b>	2024-06-08
<b>Borrower</b>	Shanghai Desano Bio-pharmaceutical Co., Ltd.
<b>Sectors</b>	Industry and Trade
<b>Investment Type(s)</b>	Loan
<b>Investment Amount (USD)</b>	\$ 100.00 million
<b>Project Cost (USD)</b>	\$ 150.00 million



---

## Project Description

According to the Bank's website, the proposed investment is a US\$100 million equivalent A loan to the Company's subsidiaries to support: (i) the construction of a new API/FDF manufacturing facility in Bangalore, India, and (ii) the expansion of an existing API manufacturing facility in Jiangxi Province, China (a frontier region), for ARV drugs targeting low- and middle-income countries (the "Project"). The Project intends to play a key role in reducing the treatment cost of HIV patients globally and enhancing the resilience of pharmaceutical supply chain through localized production.



## Early Warning System Project Analysis

This is a Category B project according to IFC's Policy on Environmental and Social Sustainability (2012). Key E&S issues include i) the Company's management and monitoring systems to assess and manage environmental and social (E&S) risks and impacts from its operations and related to the construction and operation of two new facilities funded under the project; ii) consistent management of labor and working conditions, occupational health and safety (OHS) policies and practices, iii) monitoring and management of air emissions, waste and wastewater, iv) hazardous material/waste and chemical management practices, v) life and fire safety and emergency preparedness and response, and vi) the company's stakeholder engagement activities.



---

## Investment Description

- International Finance Corporation (IFC)

The Project is expected to cost US\$150 million, which will be funded by the IFC loans of up to US\$100 million equivalent in RMB with 7-year tenor and the Company's internally generated cashflow.



---

### Private Actors Description

Headquartered in Shanghai, China, Shanghai Desano Bio-Pharmaceutical Co., Ltd. (“Desano” or the “Company”) is a leading manufacturer of Active Pharmaceutical Ingredients (“API”) and finished dosage forms (“FDF”) for the treatment of HIV-AIDS. The company sells its API products utilized by its domestic and overseas corporate drug manufacturing clients to produce generic antiretroviral (ARV) drugs. Also the company sells FDF products in China and exports them globally.

Desano is 54.28% directly and indirectly owned by its co-founder Shengping Xu. The rest is owned by employees and institutional private equity investors.



---

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Shanghai Desano Bio-pharmaceutical Co., Ltd.	Client	-

---



---

## Contact Information

Shanghai Desano Bio-Pharmaceutical Co., Ltd  
Hong Guoliang  
Finance Manager  
+86-21-51323300  
hongguoliang@desano.com  
No. 1479, Zhangheng Road, Zhangjiang Hi-Tech Park, Shanghai  
www.desano.com

## ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

## ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at [CAO@worldbankgroup.org](mailto:CAO@worldbankgroup.org) You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>





---

**Bank Documents**

- [Environmental & Social Review Summary \(ESRS\)](#)